IDEAS home Printed from https://ideas.repec.org/a/cwh/ijneur/v59y2025id105.html

Use of Cannabidiol in Neurodegenerative Diseases

Author

Listed:
  • Igor Silveira Ramalho

    (Universidad Abierta Interamericana, Facultad de Medicina y Ciencias de la Salud. Buenos Aires, Argentina)

  • Cabrera Emanuel Cristian Hugo Martinez

    (Universidad Abierta Interamericana, Facultad de Medicina y Ciencias de la Salud. Buenos Aires, Argentina)

Abstract

Background: Background: Cannabidiol (CBD) has shown neuroprotective and immunomodulatory properties in models of Alzheimer’s disease (AD), Parkinson’s disease (PD), and multiple sclerosis (MS). Objective: To synthesize quantitative evidence from four selected studies on CBD in neurodegenerative disorders. Methods: A narrative review was conducted including: one experimental study in AD (Cells 2023), one preclinical study in PD (IJMS 2021), a systematic review on MS, and a 2024 IJMS review on Cannabis compounds in neurological disorders. Results: In an AD mouse model (A 1–42), CBD treatment for 12 days improved spatial learning and memory in the Morris water maze, reduced neuroinflammation by lowering TNF- and MCP-1, and modulated inflammation-related genes (Plcg2, Ctsc, Slamf8, Prdx2, Grn). In a PD model induced by 6-hydroxydopamine (6-OHDA), CBD preserved nigrostriatal neurons, reduced apomorphine-induced rotations by 54% and limb-use asymmetry by 34%, with mechanisms involving astrocytic TRPV1 activation and increased CNTF. In MS, evidence suggests immunomodulatory effects of CBD, and nabiximols (1:1 THC: CBD) reduced spasticity in clinical trials. Conclusion: Preclinical data support neuroprotective and anti-inflammatory effects of CBD in AD and PD, while in MS, clinical benefits are suggested in combination therapies. Controlled clinical trials with isolated CBD are needed to establish efficacy, optimal dosing, and long-term safety.

Suggested Citation

Handle: RePEc:cwh:ijneur:v:59:y:2025:id:105
DOI: 10.62486/ijn2025105
as

Download full text from publisher

File URL: https://ijneurology.org/index.php/ijn/article/view/105
File Function: Abstract page
Download Restriction: no
File URL: https://ijneurology.org/index.php/ijn/article/download/105/119
File Function: Full text
Download Restriction: no
File URL: https://libkey.io/10.62486/ijn2025105?utm_source=ideas
LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
---><---

More about this item

Keywords

;
;
;
;
;

Statistics

Access and download statistics

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:cwh:ijneur:v:59:y:2025:id:105. See general information about how to correct material in RePEc.

If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

We have no bibliographic references for this item. You can help adding them by using this form .

If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Dr. Andrew Alberto López Sánchez (email available below). General contact details of provider: https://ijneurology.org/index.php/ijn .

Please note that corrections may take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.